Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance
Can an experimental PD-1 drug still offer breakthrough potential?
The FDA today said yes, handing out its breakthrough therapy designation for the newly dubbed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
